Background: The six-minute walk test (6MWT) is an established functional test assessing exercise capacity and is used to predict clinical prognosis in patients with chronic heart failure (HF). Tele-accelerometry is a novel approach to activity monitoring using telemedical data transfer and allows a Tele-6MWT to be performed in an outpatient setting. It offers patients the option of performing simple serial follow-up tests in their own home. Aims: The aim of this study was to investigate the prognostic value of serial Tele-6MWTs using tele-accelerometry in patients with HF. Design/methods: In this proof-of-concept study, 155 patients with HF completed the Tele-6MWT in an outdoor setting once per month over a period of 0.25-21 months. We analysed the differences in the number of steps over time to predict hospitalization as a result of HF or death. Results: Patients with at least one event (n ¼ 31) recorded a lower number of steps and a shorter distance in Tele-6MWT at baseline compared with patients who remained event-free (n ¼ 124) (540.1 AE 78.4 steps vs. 601.8 AE 76.7 steps, P < 0.001 respectively; 353.2 AE 82.4 m vs. 418.8 AE 95.6 m, P < 0.001). Patients (n ¼ 19) who performed more than one Tele-6MWT prior to a clinical event showed no significant difference in the number of steps, regardless of whether the baseline test was compared with the last Tele-6MWT before the event or with the last two tests before the event. Conclusion: Tele-6MWT has a high predictive value with respect to hospitalization as a result of HF or death from any cause and the results were comparable with the prognostic impact of a conventional 6MWT. Therefore Tele-6MWT may be used as alternative test method in the home environment. However, there is no added prognostic value of repeating Tele-6MWTs on a monthly basis.
Introduction
The six-minute walk test (6MWT) is a widely available diagnostic test used to assess exercise capacity in patients with chronic heart failure (HF). According to the recommendations of the American Thoracic Society, the 6MWT should be performed as a walk on a flat corridor of 30 m length accompanied by a member of the medical staff. 1 The distance walked during the 6MWT is a strong predictor for long-term mortality and hospitalization as a result of HF. However, there are limited data about the prognostic value of repeated 6MWTs. 2 Tele-accelerometry is a new diagnostic approach to activity monitoring with telemedical data transfer. It allows patients to perform the Tele-6MWT in their home environment without the need for an accompanying person. 3 In tele-accelerometry, the number of steps walked during a six-minute period is counted instead of the walking distance measured by a hand-wheel in a conventional 6MWT. When the results of the 6MWT were compared using both a conventional hand-wheel and tele-accelerometry, there was a significant correlation between the walking distance and the number of steps. This allowed the conversion of steps into distance. 4 These results are congruent with other studies evaluating the reliability of different pedometers. A decreased physical state as a result of progressive HF correlates with a decrease in the number of steps, whereas the patients' stride length remains unchanged. 5 The primary aim of this proof-of-concept study was to assess the prognostic value of repeated Tele-6MWTs to predict death from any cause or hospitalization as a result of HF during a follow-up period of 15 months.
Methods
This proof-of-concept study represents a pre-specified sub-study of the Telemedical Interventional Monitoring in Heart Failure Patients (TIM-HF) trial (clinicaltrials.gov, identifier NCT00543881). A total of 710 patients with chronic systolic HF were included in this multicentre, randomized controlled telemedical trial. The following inclusion criteria had to be fulfilled: chronic HF with New York Health Association functional class II-III, reduced left ventricular ejection fraction (LVEF) 35% and at least one hospitalization as a result of HF within 24 months prior to randomization. In patients with an LVEF 25%, proved two times within six months prior to randomization, no hospitalization as a result of HF within 24 months prior to randomization was required. 6 The TIM-HF study started in January 2008 and was terminated on a fixed date of 30 April 2010. There was an individual follow-up period for every patient lasting from the date of randomization to the fixed termination date. The median (range) follow-up period was 26 (12-28) months. Patients were randomized to a telemonitoring (TM) group (n ¼ 354) or a control group (n ¼ 356) on an intention-to-treat principle. Home-based TM included daily measurement of body weight, blood pressure, ECG and a self-assessment of well-being. Wireless data transfer was conducted from the patients' homes directly to the Telemedical Centres (TMC) at Charite´-Universita¨tsmedizin Berlin or the Robert Bosch Krankenhaus in Stuttgart, Germany. A detailed description of the telemedical system and the results of the TIM-HF trial have been reported elsewhere. 6, 7 A subgroup of telemedicine patients (155/354 patients, 43.8%) performed repeated tests with teleaccelerometry on a monthly basis. The device used (AiperMotion 300 PfH, Aipermon GmbH & Co. KG, Munich, Germany) was a customized accelerometer with a 'start' button and a programmed automatic stop of recording data after six minutes. The reliability and validity of this device and the rationale for selecting patients to participate in activity monitoring has been reported in detail elsewhere. 4 The study was carried out according to the principles of the Declaration of Helsinki (1996) and the International Conference on Harmonization Good Clinical Practice and was approved by the local ethics committee (EA1/052/07). Written informed consent was obtained from all participating patients.
Tele-6MWT procedure
Tele-6MWT was performed at baseline and then monthly over a period of 12-21 months. Baseline measurements were supervised by nurses from the TMC to train patients in using the device and to find an appropriate test area. To ensure the validity and reliability of tele-accelerometry, the instructing nurse simultaneously measured the 6MWT distance using a conventional hand-wheel at baseline and at 12 months follow-up (364 AE 30.0 days). 4 After measurement at baseline, the patients were asked to perform the test on their own once a month for the remaining follow-up period.
The data from the accelerometer were automatically transmitted to the TMC via a mobile network after the completion of each 6MWT. However, these data were not used as a part of remote patient management (RPM) in the TIM-HF trial. The data were gathered in a double-blind manner (to the patient and to the medical staff of the TMC) and were analysed retrospectively.
Statistical analyses
Statistical analysis was performed using IBM SPSS Statistics (version 22.0). Patient baseline characteristics were descriptively analysed by reporting mean AE SD values and frequencies for the quantitative measurements. Differences were compared using a two-tailed t test for normally distributed variables. In all data analyses, P < 0.05 was considered as statistically significant and these values were reported in an explorative manner. Receiver operating characteristic (ROC) analyses were performed to determine the most reliable cut-off value for the 6MWT steps according to positive/negative predictive values (PPV/NPV) in terms of classifying the patients correctly for the combined endpoint (all-cause mortality and hospitalization as a result of HF). The area under the ROC curve with 95% confidence intervals (CI) was calculated to assess the overall diagnostic performance of potential explanatory variables (6MWT steps and distance).
Results

Clinical characteristics
A total of 155 patients (mean AE SD age 67.7 AE 10.8 years) performed the Tele-6MWT once per month; 84% of the study participants were men and the mean AE SD LVEF was 27.9 AE 5.2%. The mean AE SD (range) follow-up period for all patients was 15 AE 6 (0.25-21) months.
During follow-up, 31 of 155 patients (20%) had at least one event: death of any cause and/or hospitalization as a result of HF. These 31 patients showed no significant difference in age, LVEF, body mass index or New York Health Association functional class compared with the patients who remained event-free (n ¼ 124) (Table 1 ). There were significant differences in the baseline levels of biomarkers (N-terminal pro-B-type natriuretic peptide, midregional pro-adrenomedullin and midregional pro-atrial natriuretic peptide) between patients with and without an event.
In total, 13 patients died during follow-up. Six patients died at home: for four of these patients the cause of death was classified by the endpoint committee as sudden cardiac death; one patient died as a result of end-stage cancer and one patient committed suicide. Seven patients died in hospital: five were admitted to hospital as a result of acute decompensated HF and two died in hospital from other causes (intracranial haemorrhage, incurable gut bleeding).
Death was the first event after starting Tele-6MWT without prior hospitalization as a result of HF in only five patients. Only these five patients were analysed with 'death of any cause' as the first event. In the remaining 26 patients, the first clinical event was hospitalization as a result of HF.
Results of Tele-6MWT
Patients with at least one event (n ¼ 31) recorded a lower number of steps at baseline Tele-6MWT than patients who remained event-free (n ¼ 124) A total of 22 of 31 patients performed Tele-6MWT within a time frame of 4 AE 2 weeks prior to the first event with a mean AE SD number of steps of 531.9 AE 108.5. Three of these 22 patients had their first event within the first month after the baseline test (one sudden death, two patients hospitalized as a result of HF). The remaining 19 patients performed at least one additional Tele-6MWT prior their event. There was no difference between the number of steps prior to an event and the results at baseline (À1.4 AE 112.1, À167 to 383 steps). A total of 18 of these 19 patients completed consecutive Tele-6MWTs within 84 days prior to their event. There was no significant difference in the number of steps between these consecutive tests (543.8 AE 107.5 steps vs. 528.6 AE 112.5 steps; P ¼ 0.163).
Almost two-thirds of patients (n ¼ 13/21) who were admitted to hospital as a result of HF as their first event resumed their performance of the Tele-6MWT after discharge from their first hospitalization as a result of HF. These patients completed a mean AE SD (range) of 7.9 AE 5 (1-16) additional tests post-discharge with a mean AE SD (range) of 506.8 AE 116.2 (337-666) steps. There was no significant difference between the mean number of steps before and after the first hospitalization as a result of HF (528.6 AE 114.7 steps vs. 506.8 AE 116.2 steps; P ¼ 0.386). There was also no significant pre-and post-event difference in the number of steps between patients with single or multiple hospitalizations following a first hospitalization as a result of HF. Figure 2 shows the ROC curve used to determine the optimum cut-off value of steps in the Tele-6MWT at baseline to differentiate between patients with and without an event. The corresponding area under curve values with 95% CIs for hospitalization as a result of HF were 0.73 (P < 0.001; 95% CI 0.630-0.829) for steps and 0.707 (P < 0.001; 95% CI 0.608-0.805) for distance in Tele-6MWT. A cut-off value of 495 steps was calculated to determine patients without events (rule-out) with a specificity of 90% (a sensitivity of 26%) (PPV 40%, NPV 83%).
Discussion
We have shown that the initial Tele-6MWT is a predictor for death of any cause or for hospitalization as a result of HF. Statistical analysis showed 495 steps to be the best cut-off value for risk prediction. However, patients did not show a significant difference in the number of steps achieved in monthly repeated Tele-6MWTs compared with the baseline. Thus Tele-6MWTs repeated on a monthly basis do not improve the prognostic impact of the Tele-6MWT at baseline. This finding is in agreement with other studies evaluating the prognostic value of repeated standardized 6MWTs.
In a study by Ingle et al., 8 600 patients with HF with similar clinical baseline characteristics to those in our study performed the standardized 6MWT at baseline and after 12 months. There was no significant difference in the results between the two tests. The 6MWT distances at baseline were of the same prognostic impact as those performed after 12 months in terms of allcause mortality during a follow-up period of eight years. Thus Ingle et al. 8 concluded that the repetition of 6MWTs after one year is only of limited additional value in estimating long-term prognosis. Taeger et al. 9 investigated the minimum clinically important difference (MID) between the results of repeated 6MWTs in two cohorts of stable patients with HF. The MID represents a cut-off point to distinguish normal biological variations in the test results from changes resulting from altered functional capacity. The study participants were younger and showed less severe symptoms of HF compared with the baseline characteristics in our study. A total of 461 patients in the first cohort performed a second 6MWT six months after the baseline test, whereas 512 patients in the second cohort repeated the 6MWT after 12 months. In both cohorts, the MID was 36 m between repeated tests.
Anker et al. 10 defined differences in repeated 6MWTs as a secondary endpoint in an interventional study. They investigated the efficacy of intravenous ferric carboxymaltose treatment in patients with HF and iron deficiency compared with usual HF care. The patients completed 6MWTs at baseline, at one month and at six months of follow-up. After six months, the patients who were randomized to the interventional group showed a significant increase of 36 m in the 6MWT. This result supports the finding by Taeger et al. 9 for the mean MID between repeated 6MWTs.
Thus serial follow-up of 6MWTs might have more diagnostic impact in reflecting the efficacy of a specific treatment rather than having an additional prognostic value. This could be a rationale for the concept of repeated Tele-6MWTs within the RPM of patients with HF. Our study did not show any significant difference between repeated 6MWTs prior to hospitalization as a result of HF by comparing the baseline test with the last test prior to the event or by comparing the last two tests prior to the event. Tele-6MWTs were performed on a monthly basis, resulting in a mean period of three weeks between the last Tele-6MWT and hospitalization as a result of HF. This time frame would be much too long to detect an upcoming acute cardiac decompensation. Therefore our study does not support the concept of a monthly follow-up of Tele-6MWTs. However, the frequency of repetition seems to be a very important issue with respect to diagnostic impact.
The Telemedical CHAMPION-trial investigated the efficacy of RPM based on daily transmitted data on pulmonary pressure to prevent hospitalization as a result of HF. In this trial, all patients underwent implantation of CardioMEMS, a device that allows the daily transfer of data on pulmonary pressure from an outpatient setting to a telemedical centre. The follow-up data showed an increase in pulmonary pressure as an initial sign of upcoming acute cardiac decompensation and this occurred two to three days before the onset of clinical symptoms. 11 As a consequence, it is appropriate to motivate patients to perform Tele-6MWT at least once a week. Such a concept of more frequently repeated Tele-6MWTs could be easily implemented in new clinical trials on RPM. Most patients with HF perform a daily walk of more than six minutes and the majority of patients use modern smartphones with the option of counting steps over six minutes with high reliability. 12 Therefore a specific tele-accelerometer would not be needed by most patients. Only a few patients would need limited initial assistance from an HF nurse, e.g. to find an appropriate test area close to the patient's home. This could be a walk around a playing field.
Limitations
This proof-of-concept study is highly underpowered as a result of the small number of patients, which resulted in only a small amount of Tele-6MWT data and number of clinical events. The average number of patients in observational studies analysing the prognostic value of repeated 6MWTs is about four times that in our study. 8, 9, 13 As a consequence, further statistical analyses based on interquartile comparison could not be performed. There is also evidence regarding the influence of age and sex on the 6MWT. 14 However, due to the small number of participants, this analysis could not be performed in our study. In addition, Tele-6MWTs conducted within at least 4 AE 2 weeks prior to the first event were not performed in nine of 31 patients. The reasons for their refusal to perform the Tele-6 MWT could not be identified, although a declined physical state may impede patients from performing functional tests and could therefore account for this bias.
Conclusion
The Tele-6MWT is a novel approach to assess functional capacity in patients with HF by counting the number of steps walked in an outdoor setting. It can be self-performed by a patient without additional medical staff. Tele-6MWT was shown to have a high predictive value with respect to hospitalization as a result of HF or death of any cause, which was comparable with the prognostic impact of a conventional 6MWT. Therefore Tele-6MWT may be used as an alternative test in the home environment. However, there is no added prognostic value to repeated Tele-6MWTs on a monthly basis.
